Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
KalVista Pharmaceuticals Inc has a consensus price target of $26 based on the ratings of 5 analysts. The high is $32 issued by Needham on September 6, 2024. The low is $20 issued by HC Wainwright & Co. on September 6, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Needham, and HC Wainwright & Co. on September 6, 2024, September 6, 2024, and July 15, 2024, respectively. With an average price target of $24 between HC Wainwright & Co., Needham, and HC Wainwright & Co., there's an implied 139.38% upside for KalVista Pharmaceuticals Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for KalVista Pharma (NASDAQ:KALV) was reported by Cantor Fitzgerald on September 9, 2024. The analyst firm set a price target for $0.00 expecting KALV to fall to within 12 months (a possible -100.00% downside). 13 analyst firms have reported ratings in the last year.
The latest analyst rating for KalVista Pharma (NASDAQ:KALV) was provided by Cantor Fitzgerald, and KalVista Pharma reiterated their overweight rating.
There is no last upgrade for KalVista Pharma
There is no last downgrade for KalVista Pharma.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of KalVista Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for KalVista Pharma was filed on September 9, 2024 so you should expect the next rating to be made available sometime around September 9, 2025.
While ratings are subjective and will change, the latest KalVista Pharma (KALV) rating was a reiterated with a price target of $0.00 to $0.00. The current price KalVista Pharma (KALV) is trading at is $10.03, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.